Diagnostic Assessment Reports (DARs)

DAs evaluate multiple tests in the same indication. In DAs, SCHARR-TAG systematically reviews, synthesises the clinical evidence, and constructs its own mathematical model providing estimates of cost-effectiveness to the NICE appraisal committee.

Off

2024 | 2023 | 2019 | 2018 | 2016 | 2015 | 2013 | 2012

2024

PillCam COLON 2 for detecting polyps in the colon (DAP74).

2023

Tumour profiling tests to guide adjuvant chemotherapy decisions for lymph node-positive early breast cancer (DAP71) (NIHR135822).

Quantitative faecal immunochemical tests to guide referral in primary care for people with a change in bowel habit or abdominal pain (DAP50) (NIHR135637).

2019

The EndoPredict multigene test for guiding therapy decisions in breast cancer management (16/30/03).

2018

The prognostic value of tests and assessment tools in rheumatoid arthritis (14/151/08).

2016

Sepsis: The LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi [DG20] (14/69/04).

2015

Measurement of exhaled nitric oxide concentration in asthma; NIOX MINO and NObreath (DG12) (12/60/01).

2013

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis (DG10) (10/125/01).

2012

Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation (09/62/01)